Preimplantation Genetic Testing Market Segmentation:
Procedure Type Segment Analysis
The global is segmented and analyzed for demand and supply by procedure type into preimplantation genetic diagnosis, and preimplantation genetic screening. Out of the types of procedures, the preimplantation genetic diagnosis segment is estimated to gain the largest preimplantation genetic testing market share in the year 2035. The growth of the segment can be attributed to the high efficiency of preimplantation genetic diagnosis. For high-genetic-risk couples with a known genetic condition, preimplantation genetic diagnosis (PGD) has been utilized successfully. Moreover, couples now have the chance to learn crucial genetic details about their embryos before starting a pregnancy owing to this revolutionary reproductive method. The hemoglobin illnesses thalassemia and sickle cell, the Fragile X syndrome, mental impairment condition, and muscular dystrophies are a few examples of single gene disorders for which couples frequently choose to use PGD. Preimplantation genetic diagnosis (PGD), also known as PGT-M, can be performed in conjunction with IVF to screen for more than 600 uncommon genetic disorders, including Cystic Fibrosis and premature Alzheimer's.
Application Segment Analysis
The global preimplantation genetic testing market is also segmented and analyzed for demand and supply by application into HLA typing, aneuploidy screening, IVF prognosis, and others. Amongst these four applications of preimplantation genetic testing, the HLA typing segment is expected to garner a significant share in the year 2035. HLA typing examines certain immune system-related variables, and examination can determine whether a person is healthy enough to safely donate bone marrow, cord blood, or an organ to someone in need of a transplant. Moreover, organ donors who are terminally sick or recently passed away can also undergo HLA typing. The growth of the segment is primarily attributed to the rising demand for organ transplantation and the growing need for bone marrow. A bone marrow or umbilical cord blood transplant could save around 18,000 people between the ages of 0 and 74 every year, perhaps saving their lives.
Our in-depth analysis of the global preimplantation genetic testing market includes the following segments:
|
By Technology |
|
|
By Application |
|
|
By Procedure Type |
|
|
By Products & Services |
|
|
By End User |
|
